AFMD

Affimed NV (AFMD)

Affimed NV

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AFMD

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/11	20:41	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/09/10	19:30	GlobeNewswire Inc.	Affimed to Present at the Cantor Global Healthcare Conference 2024	NASDAQ:AFMD	Affimed NV
2024/09/05	19:36	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/09/05	19:30	GlobeNewswire Inc.	Affimed Reports Second Quarter 2024 Financial Results & Business Update	NASDAQ:AFMD	Affimed NV
2024/09/03	21:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/09/03	20:45	GlobeNewswire Inc.	Affimed Appoints Shawn M. Leland as Chief Executive Officer	NASDAQ:AFMD	Affimed NV
2024/08/29	19:30	GlobeNewswire Inc.	Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024	NASDAQ:AFMD	Affimed NV
2024/06/12	20:56	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/06/12	20:13	IH Market News	U.S. Futures Rise on Fed Decision; Oil Gains on Demand Forecasts	NASDAQ:AFMD	Affimed NV
2024/06/12	19:30	GlobeNewswire Inc.	Affimed Reports First Quarter 2024 Financial Results & Business Update	NASDAQ:AFMD	Affimed NV
2024/06/07	06:13	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:AFMD	Affimed NV
2024/06/05	19:30	GlobeNewswire Inc.	Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024	NASDAQ:AFMD	Affimed NV
2024/06/03	19:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/06/02	02:02	GlobeNewswire Inc.	Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort	NASDAQ:AFMD	Affimed NV
2024/05/29	19:30	GlobeNewswire Inc.	Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer	NASDAQ:AFMD	Affimed NV
2024/05/28	19:51	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/05/28	19:30	GlobeNewswire Inc.	Affimed Announces Annual General Meeting of Shareholders	NASDAQ:AFMD	Affimed NV
2024/05/24	06:22	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/05/24	06:05	GlobeNewswire Inc.	Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	NASDAQ:AFMD	Affimed NV
2024/05/14	23:05	GlobeNewswire Inc.	Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress	NASDAQ:AFMD	Affimed NV
2024/04/24	17:05	GlobeNewswire Inc.	Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	NASDAQ:AFMD	Affimed NV
2024/03/28	19:30	GlobeNewswire Inc.	Affimed Reports 2023 Financial Results and Operational Progress	NASDAQ:AFMD	Affimed NV
2024/03/21	19:30	GlobeNewswire Inc.	Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	NASDAQ:AFMD	Affimed NV
2024/03/12	05:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/03/06	20:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/03/06	20:30	GlobeNewswire Inc.	Affimed Announces 1-for-10 Reverse Stock Split	NASDAQ:AFMD	Affimed NV
2024/01/09	06:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/01/09	06:05	GlobeNewswire Inc.	Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	NASDAQ:AFMD	Affimed NV
2024/01/08	22:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/01/08	22:00	GlobeNewswire Inc.	Affimed Announces Leadership Change and Organizational Restructuring	NASDAQ:AFMD	Affimed NV